Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Amgen in small-cell lung cancer, active.
Overview
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05740566 by Amgen, with 509 participants enrolled, started 2023-05-31. Conditions listed: Small Cell Lung Cancer (SCLC). Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares Amrubicin, Small-cell lung cancer.
- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares Amgen, Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares Amgen, Small-cell lung cancer.
- TrialPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Shares Amgen, Small-cell lung cancer.
- TrialA Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.
- TrialPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Shares Amgen, Small-cell lung cancer.